Inovio CMO granted options and RSUs

Sumner Michael John reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Sumner Michael John reported acquisition or exercise transactions in this Form 4 filing.

INOVIO PHARMACEUTICALS, INC. reported that Chief Medical Officer Michael John Sumner received new equity awards. On March 4, 2026, he was granted options to purchase 36,832 shares of common stock and 29,608 restricted stock units.

The options vest in three annual installments: 12,278 shares on February 26, 2027, and 12,277 shares on each of February 26, 2028 and February 26, 2029. The restricted stock units vest similarly: 9,870 on February 26, 2027, then 9,869 on each of February 26, 2028 and February 26, 2029. Each restricted stock unit represents a right to receive one share of common stock, and vested units may be settled in stock, cash, or a combination.

Insider Trade Summary

Grant/Award: 66,440 shares

Grant/Award 2 txns

Insider Sumner Michael John

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Option	36,832	$0.00	$0.00
Grant/Award	Restricted Stock Unit	29,608	$0.00	$0.00

Holdings After Transaction: Common Stock Option — 36,832 contracts (Direct); Restricted Stock Unit — 29,608 contracts (Direct)

Footnotes (2)

1. F1. The vesting schedule for the 36,832 options granted on March 4, 2026 was as follows: 12,278 shares will vest on February 26, 2027; 12,277 shares will vest on February 26, 2028; 12,277 shares will vest on February 26, 2029.
2. F2. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 29,608 restricted stock units granted on March 4, 2026 was as follows: 9,870 shares will vest on February 26, 2027; 9,869 shares will vest on February 26, 2028; and 9,869 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

FAQ

What insider transactions did INO report for Michael John Sumner?

INO reported that Chief Medical Officer Michael John Sumner received equity awards on March 4, 2026. He was granted 36,832 stock options and 29,608 restricted stock units, all held directly, with multi‑year vesting schedules running from February 2027 through February 2029.

How many stock options were granted to INO’s Chief Medical Officer?

Michael John Sumner was granted 36,832 common stock options on March 4, 2026. These options vest in three annual tranches: 12,278 shares on February 26, 2027, and 12,277 shares on each of February 26, 2028 and February 26, 2029.

What restricted stock units did INO grant to Michael John Sumner?

INO granted Michael John Sumner 29,608 restricted stock units on March 4, 2026. These units vest in three installments: 9,870 on February 26, 2027, and 9,869 on each of February 26, 2028 and February 26, 2029, subject to settlement terms.

How do the INO restricted stock units for Michael John Sumner settle?

Each restricted stock unit represents a contingent right to receive one INO common share. Once vested, these units can be settled in shares of common stock, cash, or a combination of both, according to the company’s equity award terms.

Over what period do INO’s new equity awards to its CMO vest?

The stock options and restricted stock units granted on March 4, 2026 vest over three years. Vesting dates are February 26, 2027, February 26, 2028, and February 26, 2029, with a portion of each award becoming exercisable or deliverable on each date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 04:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sumner Michael John

(Last) (First) (Middle)

660 W. GERMANTOWN PIKE

SUITE 110

(Street)

PLYMOUTH MEETING PA 19462

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INOVIO PHARMACEUTICALS, INC. [ INO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Option	$1.73	03/04/2026		A		36,832		(1)	02/26/2036	Common Stock	36,832	$0	36,832	D
Restricted Stock Unit	(2)	03/04/2026		A		29,608		(2)	(2)	Common Stock	29,608	$0	29,608	D

Explanation of Responses:

1. The vesting schedule for the 36,832 options granted on March 4, 2026 was as follows: 12,278 shares will vest on February 26, 2027; 12,277 shares will vest on February 26, 2028; 12,277 shares will vest on February 26, 2029.

2. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 29,608 restricted stock units granted on March 4, 2026 was as follows: 9,870 shares will vest on February 26, 2027; 9,869 shares will vest on February 26, 2028; and 9,869 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Remarks:

	/s/ Michael John Sumner	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.